Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
Clinical trial NCT03248570 · COMPLETED
Trial details
- NCT number
- NCT03248570
- Sponsor
- University of California, San Francisco
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-20
- Primary completion
- 2023-09-28
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.